### **Evolution of the Clinical Trial Consortium in South Korea**






#### Korea, The Hub of Global Clinical Trials

KoNECT was established in December 2007 with wholehearted support from the Korean government, academics and related business industries in order to meet the increasing demands for clinical trials and to strengthen the national capability by fostering professionals, core technologies and infrastructure.

> Introduction of KoNECT



#### \* International Technical Advisory Committee

Prof. Nadarajah Sree Haran	
Dr. Adam Cohen	CEO, Center for Human Drug Research
Prof. Kyoichi Ohashi	Oita University
Prof. Masahiro Takeuchi	School of Pharmaceutical Sciences Division of Biostatistics &
	Division of Pharmaceutical Medicine
Dr. Stephen Phua	CEO & Managing Director, Agenix
Dr. Richard L. Lalonde	Head of Clinical Pharmacology, Primary Care Business Unit,
	Pfizer Global Research & Development
Prof. Trevor M. Jones	
Prof. Stuart R. Walker	Founder & Vice President, CMR



#### SMO vs. ARO




























CDISC<sup>\*</sup> Strength Through Collaboration

CONSORTIUM of ACADEMIC HEALTH CENTERS for Integrative Medicine

KoNECT (Korea National Enterprise for Clinical Trials)		KCGI (Korea Clinical trials Global Initiative)		
CTC Support		Clinical Trials Information Center • DB for clinical trials information (investigators, subjects, trial designs, IND approval status, etc) • Establishing investigators network for attracting studies		Joint Global Marketing
<ul> <li>Sharing and pooling of resources between CTC's</li> <li>Planning for supporting newly established CTC's</li> <li>Sharing of information and best practices</li> </ul>	information ( subjects, trial approval stat • Establishing i			<ul> <li>Joint marketing efforts e.g. public relations activities through media and meetings</li> <li>Participation in domestic and overseas research organizations networks</li> </ul>



#### **Global Centers of Excellence Projects**

PI Institution	Consortium Participants	Project Duration	
Seoul National Univ Hospital	Seoul National Univ Hospital Seoul National Univ Bundang Hospital Chonbuk Univ Hospital	2012.11-2017.03	
Seoul Asan Hospital	Seoul Asan Hospital Ajou Univ Hospital	2012.11-2017.03	
Yonsei Univ Health System System Yonsei Univ Severance Hospitals Catholic Univ Seoul St. Mary's Hospital Inha Univ Hospital		2013.11-2018.03	
Inje Univ Busan Baik Hospital Inje Univ Busan Baik Hospital Donga Univ Hospital Chungnam Univ Hospital		2013.11-2018.03	
TBD	TBD	2014.11-2019.03	

#### **STRATEGY**

	Capabilities	Environment	BD	Network
Specialization	<ul> <li>Early phases special studies</li> <li>Experts and staff specialized in certain areas</li> </ul>	<ul> <li>Specialists in selected TA</li> <li>Special functions, facilities and equipment</li> </ul>	<ul> <li>ARO services</li> <li>IIT support (incl. RA)</li> <li>Comprehensive consulting services for drug development</li> </ul>	<ul> <li>Expand overseas network</li> <li>TA-specific collaborative models</li> </ul>
Collaboration	<ul> <li>Multicenter trials infrastructure and systems</li> <li>SOP standardization (harmonization)</li> <li>Feasibility DB</li> </ul>	<ul> <li>Support of acquisition of international HRPP accreditation</li> <li>QM(QA/QC)</li> <li>IRB review processes</li> </ul>	<ul> <li>Industry-academia collaboration ecosystem</li> <li>PM reinforcement</li> </ul>	<ul> <li>Global marketing</li> <li>Joint effort at a national level</li> </ul>



- 1000 beds
- 400 MD's
- cover all major therapeutic areas
- believe in collaboration
- → collaborative efforts?





Keys OBJECTIVES:

- Share information
- Create a new global standard
- Global competitiveness
- Extramural funding
- Political Cohesiveness





"To promote global standards and competitiveness at clinical trial centers in Asia for the benefit of industry, academia and governments, and to accelerate medical research to help patients receive the medicines they need."



# **THANK** YOU!

## ABGI

## DAUH

## Collaboration